In patients receiving ICB, the HP ratio was found to decrease due to the clearance of tumor cells characterized by high HLA-I and low PD-L1 levels, while patients with an increasing HP ratio over time had worse outcomes. The gene discussed is CD274; the disease is neoplasm.